Tvardi 10-Q: $6.1M Q3 Loss, Going Concern and Material Weaknesses Disclosed
TVRD sits 44% above its 52-week low of $0.773.
Summary
Tvardi's Q3 10-Q shows a $6.1 million net loss and $22.3 million of cash, alongside a going-concern warning and material weaknesses in internal controls. The company funded the quarter largely through ATM sales and has about $7.4 million left available under its current sales agreement prospectus supplement.
Key Events · Earnings and Guidance · TVRD
-
Q3 Net Loss Widens to $6.1M
Net loss was $6.1 million, or $(0.48) per share, versus $5.5 million, or $(0.59) per share, a year earlier. R&D rose to $4.5 million from $3.6 million on higher TTI-101 HCC trial costs.
-
Going Concern and Material Weaknesses
The 10-Q states substantial doubt exists about the company's ability to continue as a going concern and that disclosure controls were not effective at September 30, 2026 due to material weaknesses in internal control over financial reporting.
-
Cash of $22.3M, Runway Into Q3 2027
Cash and cash equivalents were $22.3 million at September 30, 2026, down from $30.8 million in cash, cash equivalents and short-term investments at December 31, 2025; management expects this to fund operations into Q3 2027 but says present resources will not cover at least one year without new capital.
-
ATM Funded the Quarter
Tvardi sold 3,110,769 shares for about $11.0 million under the Original Sales Agreement Prospectus and 853,843 shares for about $2.3 million under the New Sales Agreement Prospectus Supplement in Q3, leaving about $7.4 million available.
Analysis · TVRD · Life Sciences
The Q3 10-Q confirms the $6.1 million quarterly loss and $22.3 million cash balance already reported in the same-day 8-K, but it also puts two governance red flags on the record in full: substantial doubt about the company's ability to continue as a going concern, and material weaknesses in internal control over financial reporting that leave disclosure controls not effective as of September 30, 2026. Cash of $22.3 million is down from $30.8 million in cash, cash equivalents and short-term investments at December 31, 2025, and management says present resources will not fund planned operations for at least one year without new capital. The company has been leaning on its ATM, selling 3,964,612 shares for $13.3 million gross in Q3, with only about $7.4 million left available under the current prospectus supplement. TTI-101 HCC topline data is now expected early in Q1 2027, and the TTI-109 ulcerative colitis program still needs IND clearance and additional funding.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVRD was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.77 to $5.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.